Navigation Links
Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
Date:10/16/2008

DETROIT, Oct. 16 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced that the Company intends to release results for its second quarter of fiscal year 2009, ended September 30, 2008, on Thursday October 23, 2008.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
2. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NASA’s MESSENGER has just celebrated its 10 year anniversary ... one of its latch valves, V27200-818, operating onboard this ... of the planet Mercury. It is only the second ... a vast amount of information and images of the ... solenoids that also include permanent magnets to maintain the ...
(Date:9/16/2014)... jaw movements has been created by a group of ... device can generate electricity from eating, chewing and talking, ... electronic devices, such as hearing aids, cochlear implants, electronic ... of the device,s performance have been published today, 17 ... Structures . , Jaw movements have proved to be ...
(Date:9/16/2014)... BlueInGreen® , a water ... for delivering dissolved gases into liquids, announced the ... a manufacturer’s representative firm to its sales network. ... municipal water and wastewater applications in the Canadian ... founded in 1992 and serves Quebec and Ontario ...
(Date:9/16/2014)... 16, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... completion of the Company,s Investor Day in ... irritable bowel syndrome (IBS) program, including its novel, ... In the keynote presentation, Mark Pimentel ...
Breaking Biology Technology:'Smart material' chin strap harvests energy from chewing 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Biotech and pharma companies,are increasingly utilizing novel ... early in the development cycle to avoid ... and,Biotechnology News (GEN) ( http://www.genengnews.com/ ). By ... early, pharma also has the opportunity to ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
Cached Biology Technology:MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:9/16/2014)... show its extravagant, colorful tail feathers in courtship of ... a special camera developed by an engineer at Washington ... swordtail fish choose their mates based on a similar ... at Austin used a bioinspired polarization camera developed by ... engineering at Washington University, to make the discovery. His ...
(Date:9/16/2014)... waters of Southeast Alaska to the white sand beaches ... and tourist towns, coastal residents around the U.S. share ... along political lines. That,s a primary finding of a ... this month in the journal Society & Natural ... differences from place to place to place. Each environment ...
(Date:9/16/2014)... ethical choices such as buying clothing not made in ... and bringing their own bags when they go shopping? ... of Consumer Research , ethical consumption is motivated by ... unethical practices into action. , "Advocates of ethical consumerism ... costs of the products they choose, but unfortunately only ...
Breaking Biology News(10 mins):Camera developed at WUSTL sheds light on mate choice of swordtail fish 2Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Why are consumers willing to spend more money on ethical products? 2
... The Society of Interventional Radiology Foundation,s Discovery Campaign, ... invasive medicine into new areas of discovery, announced ... a manufacturer of medical devices, pharmaceuticals and medical ... and is a "Visionary" level supporter. ...
... In the waters off the North Carolina coast, historically-significant ... seafloor, a testament to a relatively unknown chapter in ... shipwrecks are not only important for their cultural value, ... fishes, invertebrates and algal species. Additionally, due to their ...
... by two teams of Army scientists and collaborators has identified ... virus infection. The findings, published online today in separate studies ... for combating one of the world,s most deadly viruses. ... high as 90 percent in humans. The virus is of ...
Cached Biology News:Single protein, key to ebola virus infection, could aid in drug design 2
ImageQuant 300, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
Request Info...
Recombinant Feline IL-5...
Biology Products: